Rhythm Pharmaceuticals Secures $25,000,000 Series B Financing Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=43fcab10-5811-4856-aa8b-82b65e8dd713&Preview=1 -
Date
6/4/2012 -
Company Name
Rhythm Pharmaceuticals -
Mailing Address
855 Boylston Street, 11th Floor Boston, MA 02116 -
Company Description
Rhythm is a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases. -
Website
http://www.rhythmtx.com -
Transaction Type
Venture Equity -
Transaction Amount
$25,000,000 -
Transaction Round
Series B -
Proceeds Purposes
Rhythm will use the proceeds to continue advancing its small-peptide therapeutics for metabolic diseases through Phase 2 clinical trials. RM-131 is a ghrelin agonist currently in a Phase 2 clinical trial for the treatment of diabetic gastroparesis. RM-493, an agonist of the melanocortin 4 receptor (MC4R), is currently in Phase 1 clinical trials for the treatment of obesity and diabetes. -
M&A Terms
-
Venture Investor
MPM Capital -
Venture Investor
New Enterprise Associates -
Venture Investor
Third Rock Ventures -
Venture Investor
Undisclosed
